- Library Home /
- Search Collections /
- Open Collections /
- Browse Collections /
- UBC Graduate Research /
- Early Treatment of COVID-19 Disease : A Missed Opportunity
Open Collections
UBC Graduate Research
Early Treatment of COVID-19 Disease : A Missed Opportunity Forrest, Jamie I.; Rayner, Craig R.; Park, Jay J. H.; Mills, Edward J.
Abstract
Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of disease, reducing morbidity, mortality, and the likelihood of onward transmission. At the time of writing, more than 1900 clinical trials are registered globally to assess the efficacy and safety of candidate therapeutics for COVID-19. The majority of these trials are designed to evaluate the comparative efficacy and safety of candidate therapeutics for the treatment of COVID-19 to prevent death among populations of hospitalized patients with advanced disease. Yet, emerging epidemiological evidence now indicates that the majority of those infected with the SARS-CoV-2, while still infectious, experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease evaluating not only reductions in morbidity and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for HIV and hepatitis C, and comment on the challenges and opportunities for clinical research of candidate therapeutics for early COVID-19 disease.
Item Metadata
Title |
Early Treatment of COVID-19 Disease : A Missed Opportunity
|
Creator | |
Publisher |
Springer
|
Date Issued |
2020-10-13
|
Description |
Antivirals have demonstrated efficacy in treating other infectious diseases in early stages of
disease, reducing morbidity, mortality, and the
likelihood of onward transmission. At the time
of writing, more than 1900 clinical trials are
registered globally to assess the efficacy and
safety of candidate therapeutics for COVID-19.
The majority of these trials are designed to
evaluate the comparative efficacy and safety of
candidate therapeutics for the treatment of
COVID-19 to prevent death among populations
of hospitalized patients with advanced disease.
Yet, emerging epidemiological evidence now
indicates that the majority of those infected
with the SARS-CoV-2, while still infectious,
experience minimal or mild disease symptomology. Like HIV and hepatitis C that pioneered treatment as prevention, there is a
missed opportunity for trials of early pharmaceutical intervention for COVID-19 disease
evaluating not only reductions in morbidity
and mortality but also transmissibility. We discuss this clinical research gap within an historical context of viral treatment as prevention for
HIV and hepatitis C, and comment on the
challenges and opportunities for clinical
research of candidate therapeutics for early
COVID-19 disease.
|
Subject | |
Genre | |
Type | |
Language |
eng
|
Date Available |
2021-06-15
|
Provider |
Vancouver : University of British Columbia Library
|
Rights |
Attribution-NonCommercial 4.0 International
|
DOI |
10.14288/1.0398422
|
URI | |
Affiliation | |
Campus | |
Citation |
Forrest, J. I. (10/13/2020). Early treatment of COVID-19 disease: A missed opportunity. Infectious Diseases and Therapy (ADIS).
|
Publisher DOI |
10.1007/s40121-020-00349-8
|
Peer Review Status |
Reviewed
|
Scholarly Level |
Faculty; Graduate
|
Copyright Holder |
Authors
|
Rights URI | |
Aggregated Source Repository |
DSpace
|
Item Media
Item Citations and Data
Rights
Attribution-NonCommercial 4.0 International